Keynote Address

• History, major findings and lessons learned from the Lung Cancer Mutation Consortium
  Paul A Bunn Jr, MD

Current and Future Application of Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

• Emerging research information with the use of anti-PD-1/PD-L1 antibodies in patients with previously untreated metastatic NSCLC
  Roy S Herbst, MD, PhD
• Practical assessment of PD-L1 status and integration of PD-L1 assays into clinical practice
  Joel W Neal, MD, PhD
• Current role of anti-PD-1/PD-L1 antibodies in patients with EGFR- or ALK-positive disease
  Naiyer Rizvi, MD
• Novel immunotherapeutic approaches; combination strategies with chemotherapy
  Nathan A Pennell, MD, PhD

EGFR Mutation-Positive NSCLC

• Molecular testing in clinical practice and the role of multiplex testing/next-generation sequencing (NGS)
  Paul A Bunn Jr, MD
• Effect of EGFR variant on the selection of first-line systemic therapy
  Alice Shaw, MD, PhD
• Identification of acquired resistance: Detection of T790M and other secondary mutations in tissue, plasma and urine
  Geoffrey R Oxnard, MD
• Available efficacy and safety data with osimertinib; ongoing evaluation in the first-line setting; effectiveness in patients with CNS metastases
  Roy S Herbst, MD, PhD

EML4-ALK, ROS1, BRAF and Other Potentially Targetable Mutations

• Optimal approach to ALK assessment; selection of first-line therapy for patients with ALK-rearranged or ROS1-positive NSCLC
  Alice Shaw, MD, PhD
• Approved and investigational TKIs for patients with ALK-positive disease progressing on first-line TKI therapy
  Geoffrey R Oxnard, MD
• Identification of and treatment for patients with BRAF-V600E tumor mutations
  Paul A Bunn Jr, MD
• Potential clinical benefits of and investigational opportunities associated with the identification of other oncogenic drivers (eg, HER2 and MET exon 14 skipping mutations, RET rearrangements)
  Thomas E Stinchcombe, MD

Management of Small Cell Lung Cancer, Mesothelioma and NSCLC with No Identified Targetable Mutations

• Emerging role of immune checkpoint inhibitors and ongoing clinical trials in malignant pleural mesothelioma (MPM)
  Naiyer Rizvi, MD
• Current management and ongoing clinical trials in small cell lung cancer (SCLC)
  Thomas E Stinchcombe, MD
• Sequencing of systemic therapies and clinical trial options for patients with metastatic squamous cell carcinoma (SCC)
  Mark A Socinski, MD
• Sequencing of systemic therapies and clinical trial options for patients with metastatic nonsquamous cell lung cancer
  Joel W Neal, MD, PhD
• Is there a role for targeted therapy in the adjuvant or neoadjuvant setting?
  Nathan A Pennell, MD, PhD

Quality and Value in the Management of Lung Cancer

• The oncology home: Implications for the care of patients with lung cancer
  Barbara L McAneny, MD
• What clinicians can do about the cost of cancer care
  Rogerio C Lilenbaum, MD

Lung Cancer Interdisciplinary Tumor Board

• Prognostic molecular models in early-stage lung cancer
  Eric Vallières, MD
• Radiation therapy: Challenging clinical scenarios and related management issues
  Roy H Decker, MD, PhD
• Adjuvant and neoadjuvant therapy
  Karen Kelly, MD
• Controversies in the surgical management of lung cancer
  Eric Vallières, MD
• Recent therapeutic advances and novel trial concepts for patients with locally advanced NSCLC
  Roy H Decker, MD, PhD
• Optimal management of oligometastatic disease
  Mark G Kris, MD

Practical Challenges in the Use of Immunotherapy

• Clinical complications associated with immunotherapy; immunotherapy in patients with a history of autoimmune disease
  Corey J Langer, MD
• Clinically relevant endpoints for checkpoint inhibitor trials; management approach for patients with prolonged progression-free survival: Is there a role for stopping therapy?
  Mark G Kris, MD
• Clinical trials integrating immunotherapy and radiation therapy
  Karen Kelly, MD
• Immunotherapy in elderly patients and those with significant comorbidities
  Corey J Langer, MD